Durable response to fulvestrant therapy in a hormone receptor-positive metastatic breast cancer patient with massive metastatic disease

Abstract

The choice of treatment modality in metastatic breast cancer depends on an age, performance status of the patient, comorbidities, disease dynamics, localization and number of metastatic lesions as well as an expression of hormonal receptors and HER2 receptor. Here we present the case of hormone receptor-positive postmenopausal metastatic breast cancer patient with the massive extension of the disease at presentation who were treated with fulvestrant, an estrogen receptor antagonist, after the failure of initial chemotherapy. Treatment with fulvestrant was associated with a significant improvement in physical status of the patient, weight gain, mobility and reduction of bone pain. Moreover, remission of the metastatic disease was durable.